{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:18:06Z","timestamp":1763414286951,"version":"3.45.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00284-025-04582-7","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:20:59Z","timestamp":1761726059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates"],"prefix":"10.1007","volume":"82","author":[{"given":"Khaoula","family":"Balgouthi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emel","family":"Eker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manaf","family":"AlMatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Albarri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u015fil","family":"Var","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"4568","key":"4582_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/1791013a0","volume":"179","author":"VC Barry","year":"1957","unstructured":"Barry VC et al (1957) A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179(4568):1013\u20131015. https:\/\/doi.org\/10.1038\/1791013a0","journal-title":"Nature"},{"key":"4582_CR2","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1128\/AAC.36.12.2729","volume":"36","author":"C Van Rensburg","year":"1992","unstructured":"Van Rensburg C et al (1992) Antimicrobial activities of Clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 36:2729\u20132735. https:\/\/doi.org\/10.1128\/AAC.36.12.2729","journal-title":"Antimicrob Agents Chemother"},{"key":"4582_CR3","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1128\/AAC.00395-15","volume":"59","author":"B Lechartier","year":"2015","unstructured":"Lechartier B, Cole ST (2015) Mode of action of Clofazimine and combination therapy with benzothiazinones against M. tuberculosis. Antimicrob Agents Chemother 59:4457\u20134463. https:\/\/doi.org\/10.1128\/AAC.00395-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4582_CR4","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"T Yano","year":"2011","unstructured":"Yano T et al (2011) Reduction of Clofazimine by mycobacterial type 2 NADH: Quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286:10276\u201310287. https:\/\/doi.org\/10.1074\/jbc.M110.200501","journal-title":"J Biol Chem"},{"key":"4582_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/1874467212666181126151948","volume":"12","author":"M AlMatar","year":"2019","unstructured":"AlMatar M et al (2019) Does the development of vaccines advance solutions for tuberculosis? Curr Mol Pharmacol 12:83\u2013104. https:\/\/doi.org\/10.2174\/1874467212666181126151948","journal-title":"Curr Mol Pharmacol"},{"key":"4582_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/jac\/43.5.615","volume":"43","author":"VM Reddy","year":"1999","unstructured":"Reddy VM, O\u2019Sullivan JF, Gangadharam PR (1999) Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 43:615\u2013623. https:\/\/doi.org\/10.1093\/jac\/43.5.615","journal-title":"J Antimicrob Chemother"},{"key":"4582_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000007255","volume":"46","author":"CE van Rensburg","year":"2000","unstructured":"van Rensburg CE et al (2000) In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against M. tuberculosis. Chemotherapy 46:43\u201348. https:\/\/doi.org\/10.1159\/000007255","journal-title":"Chemotherapy"},{"key":"4582_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/BF02945619","volume":"416","author":"V Barry","year":"1960","unstructured":"Barry V et al (1960) Absorption, distribution and retention of the Rimino-compounds in the experimental animal. Ir J Med Sci 416:345. https:\/\/doi.org\/10.1007\/BF02945619","journal-title":"Ir J Med Sci"},{"key":"4582_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5935\/0305-7518.19650002","volume":"36","author":"V Barry","year":"1965","unstructured":"Barry V, Conalty M (1965) The antimycobacterial activity of B 663. Lepr Rev 36:3\u20137. https:\/\/doi.org\/10.5935\/0305-7518.19650002","journal-title":"Lepr Rev"},{"key":"4582_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3109\/03602539508994208","volume":"27","author":"R O\u2019connor","year":"1995","unstructured":"O\u2019connor R, O\u2019sullivan J, O\u2019kennedy R (1995) The pharmacology, metabolism, and chemistry of Clofazimine. Drug Metab Rev 27:591\u2013614. https:\/\/doi.org\/10.3109\/03602539508994208","journal-title":"Drug Metab Rev"},{"key":"4582_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1040-8428(96)00229-6","volume":"25","author":"C Van Rensburg","year":"1997","unstructured":"Van Rensburg C, Anderson R, O\u2019sullivan J (1997) Riminophenazine compounds: Pharmacology and anti-neoplastic potential. Crit Rev Oncol\/Hematol 25:55\u201367. https:\/\/doi.org\/10.1016\/S1040-8428(96)00229-6","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"4582_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun A et al (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684\u2013692. https:\/\/doi.org\/10.1164\/rccm.201001-0077OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4582_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","volume":"17","author":"M Gopal","year":"2013","unstructured":"Gopal M et al (2013) Systematic review of Clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 17:1001\u20131007. https:\/\/doi.org\/10.5588\/ijtld.12.0144","journal-title":"Int J Tuberc Lung Dis"},{"key":"4582_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43440-020-00160-9","volume":"73","author":"M AlMatar","year":"2021","unstructured":"AlMatar M et al (2021) Efflux pump inhibitors: new updates. Pharmacol Rep 73:1\u201316. https:\/\/doi.org\/10.1007\/s43440-020-00160-9","journal-title":"Pharmacol Rep"},{"key":"4582_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02308-2016","author":"D Falzon","year":"2017","unstructured":"Falzon D et al (2017) World health organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02308-2016","journal-title":"Eur Respir J"},{"key":"4582_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","volume":"392","author":"N Ahmad","year":"2018","unstructured":"Ahmad N et al (2018) Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 392:821\u2013834. https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1","journal-title":"Lancet"},{"key":"4582_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/1871530319666191009153834","volume":"20","author":"M AlMatar","year":"2020","unstructured":"AlMatar M et al (2020) Differential expression of resistant and efflux pump genes in MDR-TB isolates. Endocrine, metabolic & immune Disorders-Drug targets (Formerly current drug targets-Immune. Endocr Metabolic Disorders) 20:271\u2013287. https:\/\/doi.org\/10.2174\/1871530319666191009153834","journal-title":"Endocr Metabolic Disorders)"},{"key":"4582_CR18","unstructured":"Organization WH (2018) Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis"},{"key":"4582_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","volume":"191","author":"AH Diacon","year":"2015","unstructured":"Diacon AH et al (2015) Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191:943\u2013953. https:\/\/doi.org\/10.1164\/rccm.201410-1801OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4582_CR20","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/jac\/dkx022","volume":"72","author":"JS Cavanaugh","year":"2017","unstructured":"Cavanaugh JS et al (2017) Susceptibilities of MDR M. tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic\/pharmacodynamic parameters. J Antimicrob Chemother 72:1678\u20131687. https:\/\/doi.org\/10.1093\/jac\/dkx022","journal-title":"J Antimicrob Chemother"},{"key":"4582_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1164\/ajrccm\/151.4.1083","volume":"151","author":"C Jagannath","year":"1995","unstructured":"Jagannath C et al (1995) Chemotherapeutic activity of Clofazimine and its analogues against M. tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 151:1083\u20131086. https:\/\/doi.org\/10.1164\/ajrccm\/151.4.1083","journal-title":"Am J Respir Crit Care Med"},{"key":"4582_CR22","doi-asserted-by":"publisher","first-page":"00900","DOI":"10.1128\/aac","volume":"61","author":"Y Pang","year":"2017","unstructured":"Pang Y et al (2017) In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and Gatifloxacin against extensively drug-resistant tuberculosis in Beijing. China Antimicrob Agents Chemother 61:00900\u201300917. https:\/\/doi.org\/10.1128\/aac","journal-title":"China Antimicrob Agents Chemother"},{"key":"4582_CR23","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","volume":"18","author":"K Aung","year":"2014","unstructured":"Aung K et al (2014) Successful \u20189-month Bangladesh regimen\u2019for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18:1180\u20131187. https:\/\/doi.org\/10.5588\/ijtld.14.0100","journal-title":"Int J Tuberc Lung Dis"},{"key":"4582_CR24","doi-asserted-by":"publisher","unstructured":"Wang Q et al (2018) Clofazimine for treatment of extensively drug-resistant pulmonary tuberculosis in China. Antimicrobial agents and chemotherapy 62:10.1128\/aac. 02149\u2009\u2013\u200902117. https:\/\/doi.org\/10.1128\/AAC.02149-17","DOI":"10.1128\/AAC.02149-17"},{"key":"4582_CR25","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/jac\/dkv150","volume":"70","author":"S Zhang","year":"2015","unstructured":"Zhang S et al (2015) Identification of novel mutations associated with Clofazimine resistance in M. tuberculosis. J Antimicrob Chemother 70:2507\u20132510. https:\/\/doi.org\/10.1093\/jac\/dkv150","journal-title":"J Antimicrob Chemother"},{"key":"4582_CR26","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1128\/AAC.00753-16","volume":"60","author":"D Almeida","year":"2016","unstructured":"Almeida D et al (2016) Mutations in PepQ confer low-level resistance to bedaquiline and Clofazimine in M. tuberculosis. Antimicrob Agents Chemother 60:4590\u20134599. https:\/\/doi.org\/10.1128\/AAC.00753-16","journal-title":"Antimicrob Agents Chemother"},{"key":"4582_CR27","doi-asserted-by":"publisher","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","volume":"9","author":"K Andries","year":"2014","unstructured":"Andries K et al (2014) Acquired resistance of M. tuberculosis to bedaquiline. PLoS ONE 9:e102135. https:\/\/doi.org\/10.1371\/journal.pone.0102135","journal-title":"PLoS ONE"},{"key":"4582_CR28","doi-asserted-by":"publisher","first-page":"e310323215266","DOI":"10.2174\/1874467217666230331081434","volume":"17","author":"O Albarri","year":"2024","unstructured":"Albarri O et al (2024) Antimicrobial resistance of clinical Klebsiella pneumoniae isolates: involvement of acrab and OqxAB efflux pumps. Curr Mol Pharmacol 17:e310323215266. https:\/\/doi.org\/10.2174\/1874467217666230331081434","journal-title":"Curr Mol Pharmacol"},{"issue":"5","key":"4582_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/1389203723666220630162920","volume":"23","author":"O Albarri","year":"2022","unstructured":"Albarri O et al (2022) Overexpression of efflux pumps acrab and OqxAB contributes to ciprofloxacin resistance in clinical isolates of K. pneumonia. Curr Protein Pept Sci 23(5):356\u2013368. https:\/\/doi.org\/10.2174\/1389203723666220630162920","journal-title":"Curr Protein Pept Sci"},{"key":"4582_CR30","doi-asserted-by":"publisher","unstructured":"Xu J (2017) et at Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrobial agents and chemotherapy 61:10.1128\/aac. 00239\u2009\u2013\u200900217. https:\/\/doi.org\/10.1128\/AAC.00239-17","DOI":"10.1128\/AAC.00239-17"},{"key":"4582_CR31","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMc1505196","volume":"373","author":"GV Bloemberg","year":"2015","unstructured":"Bloemberg GV et al (2015) Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 373:1986\u20131988. https:\/\/doi.org\/10.1056\/NEJMc1505196","journal-title":"N Engl J Med"},{"key":"4582_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1183\/09031936.00142914","volume":"45","author":"A Somoskovi","year":"2015","unstructured":"Somoskovi A et al (2015) A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 45:554\u2013557. https:\/\/doi.org\/10.1183\/09031936.00142914","journal-title":"Eur Respir J"},{"key":"4582_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.tube.2015.09.007","volume":"97","author":"S Thee","year":"2016","unstructured":"Thee S et al (2016) A review of the use of ethionamide and prothionamide in childhood tuberculosis. Tuberculosis 97:126\u2013136. https:\/\/doi.org\/10.1016\/j.tube.2015.09.007","journal-title":"Tuberculosis"},{"key":"4582_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijid.2016.10.026","volume":"56","author":"S Tiberi","year":"2017","unstructured":"Tiberi S et al (2017) Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis 56:181\u2013184. https:\/\/doi.org\/10.1016\/j.ijid.2016.10.026","journal-title":"Int J Infect Dis"},{"key":"4582_CR35","doi-asserted-by":"publisher","first-page":"214ra168","DOI":"10.1126\/scitranslmed.300735","volume":"5","author":"SP Rao","year":"2013","unstructured":"Rao SP et al (2013) Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med 5:214ra168\u2013214ra168. https:\/\/doi.org\/10.1126\/scitranslmed.300735","journal-title":"Sci Transl Med"},{"key":"4582_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2174\/1389201020666190308130343","volume":"20","author":"AlMatar","year":"2019","unstructured":"AlMatar et al (2019) Evaluation of polyphenolic profile and antibacterial activity of pomegranate juice in combination with Rifampin (R) against MDR-TB clinical isolates. Curr Pharm Biotechnol 20:317\u2013326. https:\/\/doi.org\/10.2174\/1389201020666190308130343","journal-title":"Curr Pharm Biotechnol"},{"key":"4582_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/genes12122003","volume":"12","author":"DM Rocha","year":"2021","unstructured":"Rocha DM et al (2021) The neglected contribution of streptomycin to the tuberculosis drug resistance problem. Genes 12:2003. https:\/\/doi.org\/10.3390\/genes12122003","journal-title":"Genes"},{"issue":"7","key":"4582_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ijmm.2010.04.019","volume":"1","author":"S Homolka","year":"2010","unstructured":"Homolka S et al (2010) Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. Int J Med Microbiol 1(7):489\u2013495. https:\/\/doi.org\/10.1016\/j.ijmm.2010.04.019","journal-title":"Int J Med Microbiol"},{"key":"4582_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tube.2014.02.005","volume":"94","author":"F Coll","year":"2014","unstructured":"Coll F et al (2014) PolyTB: a genomic variation map for Mycobacterium tuberculosis. Tuberculosis 94:346\u2013354. https:\/\/doi.org\/10.1016\/j.tube.2014.02.005","journal-title":"Tuberculosis"},{"key":"4582_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00002-23","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Rv1453 is associated with Clofazimine resistance in Mycobacterium tuberculosis. Microbiol Spectr 11:e00002\u201323. https:\/\/doi.org\/10.1128\/spectrum.00002-23","journal-title":"Microbiol Spectr"},{"key":"4582_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijantimicag.2014.09.012","volume":"45","author":"Z Zhang","year":"2015","unstructured":"Zhang Z et al (2015) In vitro synergistic activity of Clofazimine and other antituberculous drugs against multidrug-resistant M. tuberculosis isolates. Int J Antimicrob Agents 45:71\u201375. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.09.012","journal-title":"Int J Antimicrob Agents"},{"key":"4582_CR42","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.5588\/ijtld.11.0752","volume":"16","author":"J Xu","year":"2012","unstructured":"Xu J et al (2012) In vitro and in vivo activity of Clofazimine against M. tuberculosis persisters. Int J Tuberc Lung Dis 16:1119\u20131125. https:\/\/doi.org\/10.5588\/ijtld.11.0752","journal-title":"Int J Tuberc Lung Dis"},{"key":"4582_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/jac\/44.2.209","volume":"44","author":"H Steel","year":"1999","unstructured":"Steel H, Matlola N, Anderson R (1999) Inhibition of potassium transport and growth of mycobacteria exposed to Clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother 44:209\u2013216. https:\/\/doi.org\/10.1093\/jac\/44.2.209","journal-title":"J Antimicrob Chemother"},{"key":"4582_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijid.2020.10.081","volume":"102","author":"Y Liu","year":"2021","unstructured":"Liu Y et al (2021) Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis 102:392\u2013396. https:\/\/doi.org\/10.1016\/j.ijid.2020.10.081","journal-title":"Int J Infect Dis"},{"key":"4582_CR45","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3390\/jcm11071927","volume":"11","author":"S Park","year":"2022","unstructured":"Park S et al (2022) Investigation of Clofazimine resistance and genetic mutations in drug-resistant M. tuberculosis isolates. J Clin Med 11:1927. https:\/\/doi.org\/10.3390\/jcm11071927","journal-title":"J Clin Med"},{"key":"4582_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.tim.2018.01.005","volume":"26","author":"P Dur\u00e3o","year":"2018","unstructured":"Dur\u00e3o P et al (2018) Evolutionary mechanisms shaping the maintenance of antibiotic resistance. Trends Microbiol 26:677\u2013691. https:\/\/doi.org\/10.1016\/j.tim.2018.01.005","journal-title":"Trends Microbiol"},{"issue":"5","key":"4582_CR47","doi-asserted-by":"publisher","first-page":"378","DOI":"10.34297\/AJBSR.2020.07.001181","volume":"7","author":"OA Ayanwale","year":"2020","unstructured":"Ayanwale OA et al (2020) Mechanism of drug resistance in Mycobacterium tuberculosis. Am J Biomedical Sci Res 7(5):378\u2013383. https:\/\/doi.org\/10.34297\/AJBSR.2020.07.001181","journal-title":"Am J Biomedical Sci Res"},{"key":"4582_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jac\/dks389","volume":"68","author":"T Dey","year":"2013","unstructured":"Dey T et al (2013) Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 68:284\u2013293. https:\/\/doi.org\/10.1093\/jac\/dks389","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4582_CR49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.5588\/ijtld.17.0871","volume":"1","author":"SH Harouna","year":"2019","unstructured":"Harouna SH et al (2019) Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger. Int J Tuberc Lung Dis 1(5):625\u201330. https:\/\/doi.org\/10.5588\/ijtld.17.0871","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04582-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-025-04582-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04582-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:05:42Z","timestamp":1763409942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-025-04582-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4582"],"URL":"https:\/\/doi.org\/10.1007\/s00284-025-04582-7","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"type":"print","value":"0343-8651"},{"type":"electronic","value":"1432-0991"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest, financial or otherwise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research design was approved by the Medical Ethics Council of the Faculty of Medicine in Cukurova university, Turkey (reference number 50243401\/2024-8).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"583"}}